PMID- 15170521
OWN - NLM
STAT- MEDLINE
DCOM- 20041020
LR  - 20041117
IS  - 0939-5555 (Print)
IS  - 0939-5555 (Linking)
VI  - 83
IP  - 9
DP  - 2004 Sep
TI  - No predictive value of cytotoxic or helper T-cell precursor frequencies for 
      outcome when analyzed from the graft after stem cell transplantation.
PG  - 566-72
AB  - The predictive value of limiting dilution analyses (LDA) measuring cytotoxic and 
      helper T-lymphocyte precursor (CTLp and HTLp) frequencies for outcome after stem 
      cell transplantation (SCT) is still a matter of debate. One reason may be that 
      CTLp and HTLp frequencies are determined in peripheral blood mononuclear cells 
      (PBMC) and this responder cell population does not reflect the cell type 
      composition of the graft. We assessed whether CTLp and HTLp LDA can predict 
      complications after human leukocyte antigen (HLA)-identical SCT when CTLp and 
      HTLp frequencies are analyzed in PBMC of the respective stem cell graft [bone 
      marrow (BMMC) or granulocyte colony-stimulating factor (G-CSF)-mobilized PBMC] 
      and compared to PBMC of PB. Host-specific CTLp frequencies measured in 25 
      patients and HTLp frequencies analyzed in 6 patients were low in all responder 
      cell sources. CTLp and HTLp frequencies seen against HLA-mismatched unrelated 
      third-party cells were high, but third-party-specific CTLp and HTLp frequencies 
      were lower in G-CSF-PBMC than in PBMC ( p=0.047 for CTLp frequencies). 
      Host-specific CTLp frequencies analyzed in all responder cell sources did not 
      predict acute or chronic graft-versus-host disease (GVHD). Lower CTLp frequencies 
      were detected in all responder cell sources from patients who relapsed after SCT 
      than in patients without relapse, but the differences between both groups were 
      statistically significant only in PBMC. In conclusion, a significant correlation 
      was detected only between relapse and CTLp frequencies measured in PBMC. The 
      lower frequency of third-party-specific cells in G-CSF-PBMC indicates that the 
      mobilization procedure with G-CSF itself may influence results.
FAU - Kircher, Brigitte
AU  - Kircher B
AD  - Laboratory for Tumor and Immunobiology and Bone Marrow Transplantation Unit, 
      Department of Hematology & Oncology, Innsbruck Medical University, Anichstrasse 
      35, 6020 Innsbruck, Austria. brigitte.kircher@uklibk.ac.at
FAU - Niederwieser, Dietger
AU  - Niederwieser D
FAU - Gachter, Anne
AU  - Gachter A
FAU - Latzer, Karla
AU  - Latzer K
FAU - Eibl, Gunther
AU  - Eibl G
FAU - Gastl, Gunther
AU  - Gastl G
FAU - Nachbaur, David
AU  - Nachbaur D
LA  - eng
PT  - Journal Article
DEP - 20040529
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Chronic Disease
MH  - Graft vs Host Disease/*immunology/*pathology
MH  - Humans
MH  - Predictive Value of Tests
MH  - Recurrence
MH  - *Stem Cell Transplantation
MH  - Stem Cells/immunology/*pathology
MH  - T-Lymphocytes, Cytotoxic/*immunology/pathology
MH  - T-Lymphocytes, Helper-Inducer/*immunology/pathology
MH  - *Treatment Outcome
EDAT- 2004/06/02 05:00
MHDA- 2004/10/22 09:00
CRDT- 2004/06/02 05:00
PHST- 2004/02/03 00:00 [received]
PHST- 2004/04/29 00:00 [accepted]
PHST- 2004/06/02 05:00 [pubmed]
PHST- 2004/10/22 09:00 [medline]
PHST- 2004/06/02 05:00 [entrez]
AID - 10.1007/s00277-004-0886-3 [doi]
PST - ppublish
SO  - Ann Hematol. 2004 Sep;83(9):566-72. doi: 10.1007/s00277-004-0886-3. Epub 2004 May 
      29.